Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin

被引：22

作者：

Chang, An-Yun ^{[1
]}

Hsu, Eric ^{[1
]}

Patel, Jaimin ^{[1
]}

Li, Yiqun ^{[1
]}

Zhang, Minjie ^{[1
]}

Iguchi, Haruhisa ^{[1
]}

Rogoff, Harry A. ^{[1
]}

机构：

[1] Boston Biomed Inc, Cambridge, MA 02139 USA

来源：

MOLECULAR CANCER RESEARCH | 2019年 / 17卷 / 07期

关键词：

OXIDOREDUCTASE; 1; NQO1; CANCER; EXPRESSION; OVEREXPRESSION;

D O I：

10.1158/1541-7786.MCR-18-1242

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Napabucasin is an NAD(P) H: quinone oxidoreductase 1 (NQO1)-bioactivatable small molecule hypothesized to affect multiple oncogenic pathways. In a prespecified, retrospective analysis of the napabucasin phase III CO. 23 study, overall survival was longer for napabucasin versus placebo in patients expressing phosphorylated STAT3 (pSTAT3) in tumor cells and cells of the tumor microenvironment (TME). We hypothesized that a connection may exist between NQO1 expression in cancer cells and pSTAT3 in tumor cells and the TME. In 3D spheroid cocultures of cancer cells and cancer-associated fibroblasts, the antitumor activity of napabucasin was NQO1 dependent. The levels of cytokines such as IL6, CXCL10, and GM-CSF were higher in NQO1-positive versus NQO1deleted cocultures. These differentially secreted cytokines promoted STAT3 phosphorylation in tumor cells and the TME. NQO1-expressing, napabucasin-sensitive tumor cells can modify tumor cells and the TME to promote STAT3 phosphorylation, suggesting that pSTAT3 may be used to identify a subpopulation of patients who would likely respond to napabucasin. Implications: pSTAT3 is a potential biomarker for patient response to the anticancer drug napabucasin.

引用

页码：1429 / 1434

页数：6